Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates

Core Insights - Charles River Laboratories (CRL) reported quarterly earnings of $2.43 per share, exceeding the Zacks Consensus Estimate of $2.32 per share, but down from $2.59 per share a year ago [1] - The company achieved a revenue of $1 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.06% [3] Earnings Performance - The earnings surprise for the quarter was +4.74%, following a previous quarter where the company reported earnings of $3.12 per share against an expectation of $2.50, resulting in a surprise of +24.8% [2] - Over the last four quarters, Charles River has consistently surpassed consensus EPS estimates [2] Revenue Insights - Year-over-year revenue comparison shows a slight decrease from $1.01 billion to $1 billion [3] - The company has also topped consensus revenue estimates for four consecutive quarters [3] Stock Performance - Charles River shares have declined approximately 3.7% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - Current consensus EPS estimate for the upcoming quarter is $2.40 on revenues of $981.63 million, and for the current fiscal year, it is $10.17 on revenues of $3.98 billion [8] - The outlook for the Medical Services industry, where Charles River operates, is currently in the bottom 41% of Zacks industries, which may impact stock performance [9]